Investigating a stock’s 52-week price history, covering the range of low and high prices, can provide significant information about its present state and future potential. Adaptimmune Therapeutics Plc ADR’s current trading price is -60.99% away from its 52-week high, while its distance from the 52-week low is 90.43%. The stock’s price range during this period has varied between $0.42 and $2.05. The company, active in the Healthcare sector, saw a trading volume of around 1.09 million for the day, considerably lower average daily volume of 1.51 million observed over the last three months.
Adaptimmune Therapeutics Plc ADR’s stock has seen a smooth market performance. The company’s stock achieved a 1-year high of $2.05 on 03/08/24, and the lowest price during that time was $0.42, recorded on 11/28/23.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
How Financial Performance Impacts Market Capitalization
Adaptimmune Therapeutics Plc ADR (ADAP) has experienced a quarterly decline of -18.39% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 204.51M and boasts a workforce of 449 employees.
The Role of Moving Averages and Trading Volume in Technical Analysis
Based on Barchart.com data, the company’s moving average over the 100-day period was 1.0381, with a change in price of -0.2402. Similarly, Adaptimmune Therapeutics Plc ADR recorded 1,581,522 in trading volume during the last 100 days, posting a change of -23.10%.
How ADAP’s Debt-to-Equity Ratio Affects Financial Health
A company’s financial condition and market reputation can be evaluated using the debt-to-equity (D/E) ratio. This ratio, calculated by dividing a company’s total liabilities by its shareholders’ equity, indicates the proportion of debt a company employs to back its assets in relation to its shareholders’ equity. At the time of writing, the total D/E ratio for ADAP stands at 0.49. Similarly, the long-term debt-to-equity ratio is also 0.44.
ADAP Stock Stochastic Average
As of today, the raw stochastic average of Adaptimmune Therapeutics Plc ADR over the past 50 days is 19.64%. This is a decrease compared to the raw stochastic average of the last 20 days, which was recorded at 44.74%. Additionally, the Stochastic %K and %D values for the company were 24.22% and 13.46%, respectively, over the past 20 days.
ADAP Stock Price Performance Analysis
The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. This year’s metric has recorded a Price increase of 0.86%. However, over the past six months, we’ve seen a stronger performance of -32.79%. The price of ADAP leaped by -10.64% over the last 30 days. And in the last five days, it has surged by 8.45%.
